What Pharmacists Need to Know About Retatrutide's TRIUMPH-1 Phase 3 Results

Pharmacy Times has published a practice-focused analysis of retatrutide's TRIUMPH-1 results, outlining what community and hospital pharmacists should understand about the investigational triple-agonist as it moves closer to potential regulatory submission. The analysis emphasizes that retatrutide occupies a distinct pharmacologic category — it is neither a GLP-1 agonist like semaglutide nor a dual GIP/GLP-1 agonist like tirzepatide. The addition of glucagon receptor agonism introduces effects on energy expenditure and hepatic glucose production that single- and dual-agonist drugs do not provide. For pharmacists, this means the side-effect profile differs from established incretin therapies. While gastrointestinal effects (nausea, diarrhea, vomiting) remain the most common adverse events — consistent with the GLP-1 class — the glucagon component introduces theoretical concerns about hyperglycemia, liver enzyme elevations, and heart rate increases. The Phase 2 and TRIUMPH-1 data have not shown clinically significant hyperglycemia in treated patients, but post-marketing surveillance would be critical if the drug is approved. **Dosing and administration** Retatrutide is administered as a once-weekly subcutaneous injection using a pre-filled pen device, similar to tirzepatide. The Phase 3 program used a dose-escalation protocol starting at 2 mg and titrating up to a maintenance dose of 4 mg, 8 mg, or 12 mg over several weeks — a strategy designed to minimize gastrointestinal tolerability issues. Pharmacists will need to counsel patients on proper injection technique, rotation of injection sites (abdomen, thigh, upper arm), and the importance of adherence to the titration schedule. Missed doses have specific catch-up windows, which differ from those for weekly semaglutide and tirzepatide — an important counseling point to prevent double-dosing. **Drug interaction considerations** Retatrutide's effect on gastric emptying — a class effect of GLP-1 receptor agonism — has implications for the absorption of orally administered medications. Delayed gastric emptying can alter the pharmacokinetics of drugs with narrow therapeutic indices, including levothyroxine, warfarin, and certain anti-epileptics. Pharmacists performing medication reviews for patients initiating retatrutide should assess concurrent oral medications and consider monitoring adjustments. ## Canadian Context Canadian pharmacists play an expanding role in chronic disease management. In several provinces — including Alberta, Saskatchewan, and Nova Scotia — pharmacists have prescribing authority for certain conditions, including diabetes management. In Ontario, pharmacists can prescribe for minor ailments and administer injections. As retatrutide moves toward potential approval, Canadian pharmacy practice guidelines will need to address its place in therapy. The Canadian Pharmacists Association (CPhA) and provincial colleges will need to develop guidance on pharmacist-led initiation, monitoring, and follow-up for retatrutide — particularly in community pharmacy settings where patients may have limited access to specialist endocrinologists. Public drug coverage for weight-loss medications remains limited in Canada. Most provincial formularies cover GLP-1 agonists only for type 2 diabetes, not for obesity alone — unless patients have private insurance or pay out of pocket. Retatrutide's approval for obesity would likely trigger formulary reviews across all provinces and territories. Pharmacists will be on the front line of explaining coverage limitations to patients, identifying alternative funding pathways (such as manufacturer patient support programs), and navigating the Health Canada Special Access Programme for patients who cannot wait for formulary decisions. Pharmacists at Canadian clinical trial sites in the TRIUMPH program — particularly hospital pharmacies at the 22 Canadian sites in TRIUMPH-OUTCOMES — have already gained hands-on experience with retatrutide's preparation, storage, and dispensing requirements. Their institutional knowledge will be valuable in developing practice tools for broader pharmacy adoption. ## Sources - Pharmacy Times, "What Pharmacists Need to Know About Retatrutide's TRIUMPH-1 Phase 3 Results," June 3, 2026 - Jastreboff AM et al., N Engl J Med 2023; 389:514-526 - Eli Lilly press release, TRIUMPH-1 results, May 21, 2026 - Canadian Pharmacists Association (pharmacists.ca)